^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    troculeucel (SNK01)

    i
    Company:
    NKMAX
    Drug class:
    NK cell stimulant
    Related drugs:
    Apply
    A Study to Evaluate the Safety and Anti-tumor Activity of SNK01 (NK Cells) Administered in Combination With Chemotherapy or Chemotherapy / Cetuximab in Local Advanced or Metastatic Non-small Cell Lung Cancer Patients Who Failed Tyrosine Kinase Inhibitor Treatment (SNK_ASTER) (NCT04872634)
    Phase 1/2
    NKMAX Co., Ltd.
    Recruiting
    Last update posted :
    07/21/2021
    Initiation :
    07/08/2021
    Primary completion :
    05/26/2023
    Completion :
    05/26/2023
    EGFR • ALK • ROS1
    |
    EGFR mutation • ALK mutation • ROS1 mutation
    |
    Erbitux (cetuximab) • carboplatin • gemcitabine • troculeucel (SNK01)
    Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers (NCT04464967)
    Phase 1/2
    NKGen Biotech, Inc.
    Withdrawn
    Last update posted :
    05/12/2021
    Initiation :
    03/01/2021
    Primary completion :
    08/01/2022
    Completion :
    02/01/2023
    EGFR • HER-2
    |
    EGFR positive
    |
    Herceptin (trastuzumab) • Erbitux (cetuximab) • troculeucel (SNK01)